文献速递儿童内分泌与遗传代谢

自动胰岛素输注系统与1型糖尿病青少年血糖管理:系统综述与荟萃分析

Automated Insulin Delivery Systems and Glucose Management in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Pediatr · 2025-01-01

该系统综述与荟萃分析纳入11项随机临床试验(901名6至18岁1型糖尿病青少年),比较自动胰岛素输注(AID)系统与其他胰岛素方案。结果显示AID使用与糖化血红蛋白降低0.41%、血糖目标范围内时间(TIR)提高11.5%相关,夜间TIR提高19.7%,低血糖和高血糖时间均减少,不良事件无差异。

要点

  • AID系统使1型糖尿病青少年HbA1c降低0.41%、TIR提高11.5%。
  • 夜间血糖改善更明显:夜间TIR提高19.7%,夜间高血糖时间减少14.4%。
  • AID使用未增加不良事件风险,但仅2项研究报告生活质量变化。

核心结论

  • 与任何其他胰岛素方案相比,1型糖尿病青少年使用AID系统与多项血糖管理指标出现有临床意义的改善相关,且未增加不良事件风险。
  • AID系统对患者报告结局的疗效仍需更多数据。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、CINAHL和Cochrane Central(2017年1月至2025年3月)。
  • 纳入6至18岁1型糖尿病青少年、门诊环境中使用超过48小时的AID系统对比其他胰岛素方案的随机临床试验。
  • 共纳入11项报告HbA1c的随机临床试验(901名参与者)和10项报告TIR的随机临床试验(786名参与者)。
  • 干预持续时间均值(SD)为31(26)周,参与者中位年龄12岁(范围10.8-15.9岁),51%为女性,平均(SD)HbA1c为8.4%(1.1%),平均(SD)TIR为51%(9%)。

主要发现

  • 与任何胰岛素方案相比,AID使HbA1c降低-0.41%(95% CI,-0.58%至-0.25%;I2=39%)。
  • TIR提高11.5%(95% CI,9.3%-13.7%;I2=23%),夜间TIR提高19.7%(95% CI,17.0%-22.4%;I2=36%)。
  • 低血糖(<3.9 mmol/L)时间减少-0.32%(95% CI,-0.60%至-0.03%;I2=18%)。
  • 高血糖(>10 mmol/L)时间减少-10.8%(95% CI,-14.4%至-7.2%;I2=55%),夜间高血糖时间减少-14.4%(95% CI,-19.9%至-8.9%;I2=79%)。
  • 研究组间不良事件无差异,仅2项研究报告生活质量变化。

关键数值与推荐

  • 主要结局为TIR和HbA1c,效应量以均数差(MD)及95% CI表示。
  • 纳入标准为6至18岁1型糖尿病青少年、门诊AID使用超过48小时、对比其他胰岛素方案的随机临床试验。

临床怎么用

  • 对6至18岁1型糖尿病青少年,可考虑使用AID系统以改善HbA1c、TIR并减少高血糖和低血糖时间。
  • 夜间血糖改善尤为明显,AID或有助于减少夜间血糖波动。
  • 向家庭说明AID不增加不良事件风险,但生活质量获益证据有限。

局限性

  • 仅2项研究报告生活质量变化,患者报告结局数据不足。
  • 纳入研究干预持续时间均值为31周(SD 26周),长期疗效数据有限。
  • 部分结局异质性较高,如夜间高血糖时间I2=79%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Youth living with type 1 diabetes (T1D) are increasingly choosing automated insulin delivery (AID) systems to manage their blood glucose. Few systematic reviews meta-analyzing results from randomized clinical trials (RCTs) are available to guide decision-making. OBJECTIVE: To study the association of prolonged AID system use in an outpatient setting with measures of glucose management and quality of life in youth with T1D. DATA SOURCES: MEDLINE, Embase, CINAHL, and Cochrane Central were searched from January 2017 to March 2025 to identify eligible RCTs. STUDY SELECTION: Two reviewers independently performed literature screening, data extraction, and quality assessment. Included in the analysis were RCTs of youth aged 6 to 18 years with T1D that assessed the efficacy of AID systems in outpatient settings longer than 48 hours compared with any other insulin regimen. DATA EXTRACTION AND SYNTHESIS: Two reviewers performed data extraction and quality assessment independently and reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and PRISMA literature search extension guidelines. Random-effects meta-analysis models were used to estimate the pooled measures of efficacy as a mean difference (MD) with 95% CIs for outcomes measures. MAIN OUTCOMES AND MEASURES: The 2 primary outcome measures were time in range (TIR) and glycated hemoglobin (HbA1c). RESULTS: Of 2363 citations retrieved, 11 RCTs (n = 901 participants) with measures of HbA1c and 10 RCTs (n = 786 participants) with measures of TIR were included. RCTs tested interventions lasting a mean (SD) of 31 (26) weeks on youth with a median age of 12 years (range, 10.8-15.9 years); 51% were female, mean (SD) HbA1c level was 8.4% (1.1%), and mean (SD) TIR was 51% (9%). Random-effects models revealed that, compared with any insulin regimen, HbA1c level was reduced -0.41% (95% CI, -0.58% to -0.25%; I2 = 39%), whereas TIR increased 11.5% (95% CI, 9.3%-13.7%; I2 = 23%) with nighttime TIR increasing 19.7% (95% CI, 17.0%-22.4%; I2 = 36%). Random-effects models also revealed that AID use was associated with reduced time spent in hypoglycemia (<3.9 mml/L; MD = -0.32%; 95% CI, -0.60% to -0.03%; I2 = 18%) and hyperglycemia (>10 mmol/L; MD = -10.8%; 95% CI, -14.4% to -7.2%; I2 = 55%), particularly during the night (MD = -14.4%; 95% CI, -19.9% to -8.9%; I2 = 79%) compared with any insulin regimen. There were no differences in adverse events between study arms. Only 2 studies reported changes in QOL. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis found that compared with any other insulin regimen, use of AID systems by youth with T1D was associated with clinically meaningful improvements in multiple measures of glucose management, including the risk of both hyperglycemia and hypoglycemia, without increasing the risk of adverse events. More data are needed on the efficacy of AID systems on patient report outcomes.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. de Visser HS, Waraich S, Chhabra M, et al. Automated Insulin Delivery Systems and Glucose Management in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-Analysis. JAMA Pediatr. 2025. PMID: 40920375. doi:10.1001/jamapediatrics.2025.2740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。